Melanotan II is a lab-made copy of alpha-MSH, the hormone that tells skin cells to make pigment. It was studied decades ago but never approved, and it is sold online and in gyms as a tanning and libido product. Two relatives from the same melanocortin family did reach the market: afamelanotide (Scenesse) for a rare light-sensitivity disorder and setmelanotide (Imcivree) for rare genetic obesity.
The FDA's Pharmacy Compounding Advisory Committee plans to review Melanotan II, along with GHK-Cu, LL-37, dihexa, and PEG-MGF, at a meeting before the end of February 2027. The question is whether compounding pharmacies may make it from bulk ingredients; a vote would not make it an approved drug.
Safety concerns center on moles and melanoma. In a case published in JAAD Case Reports in fall 2026, a 46-year-old man with a past melanoma developed a new early-stage melanoma weeks after starting daily injections bought at a gym, though tanning beds and his history may also have played a part.
See our PCAC review explainer, #gray-market, and #pcac.
Doctors in Illinois and Michigan described in JAAD Case Reports a 46-year-old man with a history of melanoma who began daily injections of Melanotan II, an unapproved tanning peptide, bought at a local gym, Gizmodo reported on October 8, 2026. About five weeks later he noticed moles changing size, shape, and color and stopped; a biopsy about a month after that confirmed an early-stage melanoma. He also used tanning beds two to three times a week and had taken anabolic steroids, so the authors could not rule out other causes, and they warned about unregulated peptides promoted on social media.
LEO Pharma announced Tuesday August 18, 2026 an agreement to acquire worldwide rights to dersimelagon (formerly MT-7117) from Japanese drugmaker Mitsubishi Tanabe Pharma. Dersimelagon is a selective melanocortin-1 receptor (MC1R) agonist small-molecule compound being developed for erythropoietic protoporphyria (EPP) and X-linked erythropoietic protoporphyria (XLEPP), rare inherited photodermatoses in which patients develop severe skin pain and burning after light exposure. Dersimelagon is currently in Phase 3 trials across multiple rare photodermatoses indications. The mechanism: MC1R agonism stimulates skin cells (melanocytes) to produce more melanin, which absorbs light and reduces the pain-generating reaction to sun exposure that characterizes EPP. Dersimelagon represents an oral small-molecule alternative to the currently-approved injectable melanocortin-axis therapies including Clinuvel's Scenesse (afamelanotide, an alpha-MSH analog peptide administered as a subcutaneous implant for EPP, approved US 2019) and adjacent to Rhythm Pharmaceuticals' IMCIVREE (setmelanotide, an MC4R agonist peptide for rare genetic obesity syndromes and acquired hypothalamic obesity, approved US 2020 with the acquired hypothalamic obesity extension approved June 2026). The LEO Pharma acquisition extends the melanocortin therapeutic franchise landscape and positions LEO for a broader dermatology and rare-disease portfolio alongside its existing psoriasis and atopic dermatitis commercial franchises. Financial terms were not fully disclosed. The transaction adds to the growing melanocortin-axis drug development activity across peptide (afamelanotide, setmelanotide, melanotan II) and small-molecule (dersimelagon) modalities.
The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).